MyAverix Finance MyAverix Finance

WAR · Healthcare

Ryvu Therapeutics SA (RVU)

Biotechnology

Ryvu Therapeutics SA (RVU) is listed on WAR in the Healthcare sector. Industry: Biotechnology. As of 2026-05-24, reported P/E ratio is 25.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Data as of 2026-05-24

Download on the App Store Get it on Google Play

Download free on iPhone and Android

Key metrics for RVU

P/E ratio
25.00

Ryvu Therapeutics SA (RVU) — FAQ

What is RVU's P/E ratio?

The price-to-earnings (P/E) ratio for Ryvu Therapeutics SA (RVU) is 25.00 (data as of 2026-05-24).

Does Ryvu Therapeutics SA pay a dividend?

Dividend yield is not available in the current snapshot for Ryvu Therapeutics SA (RVU). Check the MyAverix Finance app for the latest dividend data.

What sector is Ryvu Therapeutics SA in?

Ryvu Therapeutics SA (RVU) is classified in the Healthcare sector (Biotechnology industry).

What exchange is RVU listed on?

RVU is listed on WAR.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

Related Healthcare companies

Abbott Laboratories (ABT) AbbVie Inc. CDR (ABBV) Agilent Technologies Inc. (A1GI34) Aimed Bio (0009K0) Alnylam Pharmaceuticals, Inc. (A1LN34) Alvotech (ALVO) Amgen Inc (AMGN34) argenx SE (A1RG34)

← All stocks

MyAverix Finance provides company information and financial data for educational and research purposes only. We are not a broker, advisor, or investment service. Data may be delayed or incomplete. Past performance does not guarantee future results. Always do your own research before making financial decisions.

Terms of Use

App Store Google Play